Expressive writing to reduce depressive and anxiety symptoms among sexual minority veterans: Study design for a pilot randomized controlled trial
Abstract
Background: Sexual minority veterans (e.g., gay, lesbian, bisexual) are at increased risk for depression and anxiety due in part to the experience of sexual minority stressors. However, few interventions target distress related to sexual minority stressors, and even fewer have been tested in Veterans Health Administration (VHA). Brief, easy to implement interventions, such as expressive writing-based interventions, that target distress related to sexual minority stressors are needed to reduce disparities in depression and anxiety.
Method: We describe the design of a two-phase study consisting of an open trial and a pilot randomized controlled trial (RCT) comparing Expressive Writing on Minority Stressors (EWMS) and a neutral writing condition among sexual minority veterans. The EWMS protocol will be iteratively refined in a case series (n = 10) and then tested in a pilot randomized control trial (RCT; n = 54). Aims of the pilot RCT are to: 1) demonstrate feasibility and acceptability of study procedures and EWMS using quantitative and qualitative data; and 2) examine preliminary trends in depressive and anxiety symptoms to inform the design of a future, fully powered efficacy trial. Participants will be assessed at baseline, posttreatment, and 3 months after treatment. Qualitative exit interviews will be conducted to inform refinements to the intervention with an eye towards usefulness, satisfaction, and implementation.
Conclusions: This pilot RCT will inform the first fully…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 54 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.